ARID1A and small cell lung carcinoma: Finally, we unveiled that ARID1A loss constituted vulnerabilities to be harnessed therapeutically by BET inhibitors, while the ARID1A-targeting compound BRD-K98645985 showed potent single-agent activity and synergistic efficacy with JQ1, revealing a novel combinatorial strategy against SCLC.